Astrazeneca's BREZTRI AEROSPHERE met all primary endpoints in the Phase III KALOS and LOGOS trials for uncontrolled asthma, suggesting a significant improvement in lung function over dual-combination therapies. These results could potentially change the standard of care for asthma patients who remain uncontrolled despite current treatments.
The KALOS and LOGOS trials were designed to test the efficacy and safety of BREZTRI, which combines budesonide, glycopyrronium, and formoterol fumarate, in comparison with inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medications. The study included approximately 4,400 patients, with results indicating an improvement in lung function as measured by forced expiratory volume in one second (FEV1).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.